innosferaНаука и инновацииScience and Innovations1818-98572412-9372Издательский дом «Белорусская наука»10.29235/1818-9857-2023-02-38-42innosfera-388Research ArticleТЕМА НОМЕРА: ВИРУСНЫЕ УГРОЗЫ НАШЕГО ВРЕМЕНИТЕМА НОМЕРА: ВИРУСНЫЕ УГРОЗЫ НАШЕГО ВРЕМЕНИНатуральная оспа и оспа обезьян: характеристика вирусо-возбудителей и меры противодействияSmallpox and monkeypox: characterization of viruses and prevention of infectionsБобрукевичД.BabrukevichD.

Дарья Бобрукевич, младший научный сотрудник лаборатории иммунологии и клеточной биофизики

г. Минск

Darya Babrukevich

bobrukevich.darya@gmail.comГончаровА.HancharouA.

Андрей Гончаров, директор, кандидат медицинских наук, доцент

г. Минск

Andrei Hancharou

andrei.hancharou@gmail.comАнтоневичН.AntonevichN.

Наталья Антоневич, заведующая лабораторией иммунологии и клеточной биофизики, кандидат биологических наук

г. Минск

Natalia Antonevich

antonevich.n@gmail.comБогданВ.BogdanV.

Василий Богдан, академик-секретарь, доктор медицинских наук, профессор

г. Минск

Vasily Bogdan

bogdan-5@mail.ruИнститут биофизики и клеточной инженерии НАН БеларусиBelarusОтделение медицинских наук НАН БеларусиBelarus202304032023023842Copyright © Издательский дом «Белорусская наука», 20232023Издательский дом «Белорусская наука»Издательский дом «Белорусская наука»https://innosfera.belnauka.by/jour/about/submissions#copyrightNoticehttps://innosfera.belnauka.by/jour/article/view/388

В данной статье рассмотрена одна из наиболее опасных и актуальных биологических угроз – поксвирусы, возбудители натуральной оспы и оспы обезьян. Авторами изложены общая характеристика, исторические аспекты заболеваний, вызываемых поксвирусами, вакцинопрофилактика и возможности специфического лечения.

This review addresses the poxviruses which are the most dangerous and urgent biological threats, especially smallpox and monkeypox. The authors discuss general characteristics of viruses, historical aspects of diseases caused by these pathogens, vaccination and control and treatment of viral infections.

поксвирусынатуральная оспаоспа обезьянpoxyvirusessmallpoxmonkeypox openness of the economyReferencesSmallpox and Monkeypox Viruses / S. Parker [et al.] // Encyclopedia of Virology. 2008. 3rd edition. P. 639–644.Smallpox and Monkeypox Viruses / S. Parker [et al.] // Encyclopedia of Virology. 2008. 3rd edition. P. 639–644.The Origin of the Variola Virus / I. V. Babkin, I. N. Babkina // Viruses. 2015. Vol. 7, №3. P. 1100–1112.The Origin of the Variola Virus / I. V. Babkin, I. N. Babkina // Viruses. 2015. Vol. 7, №3. P. 1100–1112.History of Smallpox and Its Spread in Human Populations / C. Thèves, E. Crubezy, P. Biagini // Microbiology Spectrum. 2016. Vol. 4, №4. Р. 1–10.History of Smallpox and Its Spread in Human Populations / C. Thèves, E. Crubezy, P. Biagini // Microbiology Spectrum. 2016. Vol. 4, №4. Р. 1–10.Monkeypox, a Literature Review: What Is New and Where Does This concerning Virus Come From? / G. Tiecco [et al.] // Viruses. 2022. Vol. 14, №9. Р. 1–13.Monkeypox, a Literature Review: What Is New and Where Does This concerning Virus Come From? / G. Tiecco [et al.] // Viruses. 2022. Vol. 14, №9. Р. 1–13.Preparedness for a monkeypox outbreak / Q. Luo, J. Han // Infectious Medicine. 2022. Vol.1, №2. P. 124–134.Preparedness for a monkeypox outbreak / Q. Luo, J. Han // Infectious Medicine. 2022. Vol.1, №2. P. 124–134.Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution / E. Alakunle [et al.] // Viruses. 2020. Vol. 12, №11. Article 1257. doi:10.3390/v12111257.Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution / E. Alakunle [et al.] // Viruses. 2020. Vol. 12, №11. Article 1257. doi:10.3390/v12111257.World Health Organization // https://www.who.int.World Health Organization // https://www.who.int.Gruber Marion F. Current status of monkeypox vaccines / Marion F. Gruber // npj Vaccines. 2022. Vol. 94, №7. P. 1–3.Gruber Marion F. Current status of monkeypox vaccines / Marion F. Gruber // npj Vaccines. 2022. Vol. 94, №7. P. 1–3.Preparedness for a monkeypox outbreak / Q. Luo, J. Han // Infectious Medicine. 2022. Vol.1, №2. P. 124–134.Preparedness for a monkeypox outbreak / Q. Luo, J. Han // Infectious Medicine. 2022. Vol.1, №2. P. 124–134.Prevention and Treatment of Monkeypox / John G. Rizk [et al.] // Drugs. 2022. Vol.82. P. 957–963.Prevention and Treatment of Monkeypox / John G. Rizk [et al.] // Drugs. 2022. Vol.82. P. 957–963.Challenges and Achievements in Prevention and Treatment of Smallpox / S. Melamed, T. Israely, N. Paran // Vaccines. 2018. Vol. 6, №1. P. 1–20.Challenges and Achievements in Prevention and Treatment of Smallpox / S. Melamed, T. Israely, N. Paran // Vaccines. 2018. Vol. 6, №1. P. 1–20.Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox / T. Kaever [et al.] // J. Virol. 2016. Vol. 90, №9. P. 4334–4345.Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox / T. Kaever [et al.] // J. Virol. 2016. Vol. 90, №9. P. 4334–4345.Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks / Md. Rabiul Islam [et al.] // Health Science Reports. 2022. Vol. 5, №5. P. 1–10.Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks / Md. Rabiul Islam [et al.] // Health Science Reports. 2022. Vol. 5, №5. P. 1–10.Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections / I. Gilchuk [et al.] // Cell. 2016. Vol. 167, №3. P. 684–694.Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections / I. Gilchuk [et al.] // Cell. 2016. Vol. 167, №3. P. 684–694.A Cross-Sectional Serosurvey of Anti-Orthopoxvirus Antibodies in Central and Western Africa / Siv Aina J. Leendertz [et al.] // Viruses. 2017. Vol. 9, №10. P. 1–12.A Cross-Sectional Serosurvey of Anti-Orthopoxvirus Antibodies in Central and Western Africa / Siv Aina J. Leendertz [et al.] // Viruses. 2017. Vol. 9, №10. P. 1–12.

The authors declare that there are no conflicts of interest present.